BR112012023039A2 - pirimidina substituída como um antagonista de receptor prostaglandina d2 - Google Patents
pirimidina substituída como um antagonista de receptor prostaglandina d2Info
- Publication number
- BR112012023039A2 BR112012023039A2 BR112012023039A BR112012023039A BR112012023039A2 BR 112012023039 A2 BR112012023039 A2 BR 112012023039A2 BR 112012023039 A BR112012023039 A BR 112012023039A BR 112012023039 A BR112012023039 A BR 112012023039A BR 112012023039 A2 BR112012023039 A2 BR 112012023039A2
- Authority
- BR
- Brazil
- Prior art keywords
- prostaglandin
- receptor antagonist
- compound
- substituted pyrimidine
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
pirimidina substituída como um antagonista de receptor prostaglandina d2. a presente invenção refere-se a um composto de amino pirimidina 2,6-substituída-4-monossubstituída da fórmula (i) tal como aqui apresentado, ou um enantiômero do mesmo, ou uma pró-fármaco de éster ou um sal farmaceuticamente aceitável do mesmo, ou uma composição farmacêutica que comprende tal composto. a invenção também inclui um método de tratamento de um paciente mediante a administração de uma quantidade farmaceuticamente eficaz de tal composto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31442110P | 2010-03-16 | 2010-03-16 | |
| PCT/US2011/028433 WO2011115943A1 (en) | 2010-03-16 | 2011-03-15 | A substituted pyrimidine as a prostaglandin d2 receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012023039A2 true BR112012023039A2 (pt) | 2016-05-17 |
Family
ID=43991061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012023039A BR112012023039A2 (pt) | 2010-03-16 | 2011-03-15 | pirimidina substituída como um antagonista de receptor prostaglandina d2 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130005741A1 (pt) |
| EP (1) | EP2547673A1 (pt) |
| JP (1) | JP2013522307A (pt) |
| KR (1) | KR20130008043A (pt) |
| CN (1) | CN103025726A (pt) |
| AR (1) | AR080527A1 (pt) |
| AU (1) | AU2011227420A1 (pt) |
| BR (1) | BR112012023039A2 (pt) |
| CA (1) | CA2793324A1 (pt) |
| MX (1) | MX2012010038A (pt) |
| RU (1) | RU2012143978A (pt) |
| SG (1) | SG183531A1 (pt) |
| TW (1) | TW201204708A (pt) |
| UY (1) | UY33279A (pt) |
| WO (1) | WO2011115943A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201318624A (zh) * | 2011-09-29 | 2013-05-16 | Shionogi & Co | 包含ｐｇｄ２拮抗劑及組織胺拮抗劑之過敏性鼻炎治療用醫藥 |
| EP3382391A1 (en) | 2012-10-24 | 2018-10-03 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| WO2018049271A1 (en) | 2016-09-09 | 2018-03-15 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
| US20200264188A1 (en) | 2017-09-13 | 2020-08-20 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7697298A (en) | 1997-05-29 | 1998-12-30 | Eli Lilly And Company | Process for preparing heterocyclic compounds |
| AU4971600A (en) | 1999-05-21 | 2000-12-12 | Eli Lilly And Company | Immunopotentiator agents |
| DE60115411D1 (de) | 2000-04-12 | 2006-01-05 | Merck Frosst Canada & Co Kirkl | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| DOP2007000068A (es) * | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
| WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
-
2011
- 2011-03-15 WO PCT/US2011/028433 patent/WO2011115943A1/en active Application Filing
- 2011-03-15 TW TW100108624A patent/TW201204708A/zh unknown
- 2011-03-15 BR BR112012023039A patent/BR112012023039A2/pt not_active Application Discontinuation
- 2011-03-15 JP JP2013500143A patent/JP2013522307A/ja not_active Withdrawn
- 2011-03-15 RU RU2012143978/04A patent/RU2012143978A/ru unknown
- 2011-03-15 SG SG2012063897A patent/SG183531A1/en unknown
- 2011-03-15 MX MX2012010038A patent/MX2012010038A/es not_active Application Discontinuation
- 2011-03-15 AU AU2011227420A patent/AU2011227420A1/en not_active Abandoned
- 2011-03-15 CA CA2793324A patent/CA2793324A1/en not_active Abandoned
- 2011-03-15 KR KR1020127026827A patent/KR20130008043A/ko not_active Application Discontinuation
- 2011-03-15 EP EP11710375A patent/EP2547673A1/en not_active Withdrawn
- 2011-03-15 AR ARP110100828A patent/AR080527A1/es unknown
- 2011-03-15 CN CN2011800243949A patent/CN103025726A/zh active Pending
- 2011-03-16 UY UY0001033279A patent/UY33279A/es not_active Application Discontinuation
-
2012
- 2012-09-11 US US13/610,005 patent/US20130005741A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130008043A (ko) | 2013-01-21 |
| WO2011115943A1 (en) | 2011-09-22 |
| CA2793324A1 (en) | 2011-09-22 |
| AU2011227420A1 (en) | 2012-10-04 |
| AR080527A1 (es) | 2012-04-11 |
| TW201204708A (en) | 2012-02-01 |
| JP2013522307A (ja) | 2013-06-13 |
| EP2547673A1 (en) | 2013-01-23 |
| MX2012010038A (es) | 2012-10-01 |
| CN103025726A (zh) | 2013-04-03 |
| US20130005741A1 (en) | 2013-01-03 |
| SG183531A1 (en) | 2012-10-30 |
| UY33279A (es) | 2011-10-31 |
| RU2012143978A (ru) | 2014-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012023178A2 (pt) | ramidinas substituídas como antagonistas de receptor prostaglandina 2 | |
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| PH12018500147A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
| EA201490320A1 (ru) | Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| CO6630184A2 (es) | Formulaciones famacéuticas que comprenden derivados de 1 (beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de sglt | |
| BR112015028452A2 (pt) | agonistas do receptor somastatina subtipo 4 (sstr4) | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| UA105229C2 (uk) | Фармацевтичний склад | |
| MX358961B (es) | Compuestos de tetraciclina sustituidos con fluor en c7. | |
| EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| PH12015501752A1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| MX2021010046A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
| IN2012DN02502A (pt) | ||
| BRPI1014802B8 (pt) | profármacos de triptolida. | |
| MX364400B (es) | Compuestos de tetraciclina. | |
| EA201391524A1 (ru) | Производные гликозида и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |